Madzou Moukassa VBF1,2,5*, Onanga Koumou1,2, Malanda Félix1,2, Loumingou JR1,2, Mahoungou Gael1,2, Simo Loukdom Josué4,2, Mokondjimobé Etienne1, Makélé Mabika Bleine1, Malanda Kiminou Privat1,2, Massala Péya Jethro1 and Elira Dokékias Alexis1,2
1Faculty of Health Sciences, Congo
2Brazzaville University Hospital Center, Congo
3Sickle Cell Disease National Reference Center, Congo
4University of Mountains, Cameroon
5General Office and Logistics Laboratory, Congo
*Corresponding Author: Madzou Moukassa VBF, Hospital Biologist, Biochemistry and Molecular Biology Specialty, Faculty of Health Sciences, Congo.
Received: January 09, 2023; Published: April 12, 2023
The main objective of this study was to evaluate advanced oxidation protein products (AOPPs) in sickle cell nephropathy. This was a case-control study of 70 patients. They were subdivided into 2 groups: The group of 30 patients with nephropathy called the case group and the control group consisting of 40 people, subdivided into 2 groups: the T1 group with 20 SS patients without nephropathy and the T2 group with 20 AA patients without nephropathy. There was a small increase in the AOPPs in the group of patients with nephropathy compared with the control group (P = 0.053). Renal biomarkers showed no statistically significant difference (P > 0.05). No correlation was found between AOPPs and renal clearance and between AOPPs and microalbuminuria (r = 0,07; r = 0,043 and P > 0,05). The small sample size of this study does not allow the necessary conclusions to be drawn regarding the effects of AOPPs in sickle cell disease in the Congolese population, especially as this is a preliminary study.
Keywords: Sickle Cell Disease; Nephropathy; Advanced Oxidation Protein Products (Aopp)
Citation: Madzou Moukassa VBF., et al. “Evaluation of Advanced Oxidation Protein Products in Sickle Cell Disease in Brazzaville”.Acta Scientific Medical Sciences 7.5 (2023): 91-95.
Copyright: © 2023 Madzou Moukassa VBF., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.